DexCom Inc(DXCM)stock report

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

DEXCOM (DXCM) 是一个非常有趣的公司,它面向巨大的市场。它提供了连续的血糖监测(CGM)系.统,而无需实际抽血,这个系统可以实时监控结果,并且卫生专业人员可以通过智能手机进行查看。他们与Verily技术达成了合作,并且最近与礼来公司签署了协议。根据非排他性协议的条款,礼来将在旨在帮助改善糖尿病管理的系统和泵式胰岛素输送平台中使用Dexcom的连续葡萄糖监测设备,该协议在不到一周前就已发布。我认为该排他性协议的全部利益并未完全体现在股价中。让我们看一下图表。

Current cash:1430M, Latest quarter loss:10.5M,去年亏损124M,可以烧10年。

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.4306 -147.94% 141.94%
 2019.3.31 -0.2955 -6.60% 79.34%
2019.6.30 -0.41 -685.71% -38.75%
 2019.9.30 0.09 -85.00% 121.95%


Date Sales % last year % last quarter
2018.12.31 1032M 43.58% 32.75%
 2019.3.31 281M 52.12% -72.77%
2019.6.30 617M 44.51% 119.57%
 2019.9.30 1013M 46.08% 64.18%


Insider Transactions:

Institution Ownership:


Analyst Ratings:


Leave a Reply